Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditio... Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo's two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. Mehr anzeigen
SARASOTA, FL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and...
SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel...
IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing first animal studies SARASOTA, FL, Jan. 02, 2025...
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”...
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the...
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.2818 | -14.6010362694 | 1.93 | 2.09 | 1.61 | 170838 | 1.88210338 | CS |
| 4 | 0.6985 | 73.5495419606 | 0.9497 | 3.3699 | 0.91 | 10473896 | 1.71510949 | CS |
| 12 | 0.3782 | 29.7795275591 | 1.27 | 3.3699 | 0.77 | 3583502 | 1.65692155 | CS |
| 26 | -0.4818 | -22.6197183099 | 2.13 | 3.3699 | 0.77 | 1674672 | 1.62451231 | CS |
| 52 | 0.1082 | 7.02597402597 | 1.54 | 4.5 | 0.77 | 2162891 | 2.27162677 | CS |
| 156 | -4.9518 | -75.0272727273 | 6.6 | 7.26 | 0.77 | 1063279 | 2.33909003 | CS |
| 260 | -4.9518 | -75.0272727273 | 6.6 | 7.26 | 0.77 | 1063279 | 2.33909003 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 731,1M |
| NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,5M |
| RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 341,8M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 237,15M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,44M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
